Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial.
Cheng Zhou, Chunjun Yang, Weixin Fan, Jiyuan Wu, Dingquan Yang, Hongzhong Jin, Qinping Yang, Guohong Hu, Nengxing Lin, Xiumin Yang, Jianji Wan, Jianglin Zhang, Liming Wu, Yeqin Dai, Lili Ma, Shanshan Li, Juan Su, Jianfang Sun, Yangfeng Ding, Rong Xiao, Su Zhang, Wenwen Jiang, Lihao Wang, Jianzhong Zhang
J Am Acad Dermatol 94(1) 161-171
摘要
摘要
BACKGROUND: Ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, demonstrated efficacy in a phase 2 trial for moderate-to-severe alopecia areata (AA). OBJECTIVE: To evaluate the efficacy and safety of ivarmacitinib in adults with severe AA (≥50% scalp hair loss, including alopecia totalis/universalis). METHODS: In this randomized, double-blind, phase 3 trial, 330 patients were assigned (1:1:1) to ivarmacitinib 4 mg, 8 mg, or placebo once daily for 24 weeks. Placebo recipients were re-randomized to ivarmacitinib for a 28-week extension. The primary endpoint was the proportion achieving a Severity of Alopecia Tool (SALT) score ≤20 at week 24. RESULTS: At week 24, SALT ≤20 was achieved by 34.9% (4 mg), 40.6% (8 mg), and 9.0% (placebo). Absolute differences versus placebo were 25.6% (95% CI: 15.4-35.7) for 4 mg and 31.6% (21.5-41.8) for 8 mg (both P < .0001). Treatment-emergent adverse events occurred in 77.1%, 84.7%, and 75.5% of patients, respectively; most were mild or moderate. No deaths, major cardiovascular events, or thromboembolic events were reported. LIMITATION: No active comparator was used. CONCLUSION: Once-daily ivarmacitinib 4 mg or 8 mg resulted in meaningful hair regrowth and demonstrated an acceptable safety profile in patients with severe AA.
KM 提取结果
0 个 Figure · 0 个 KM 面板